Boston Scientific Announces Results For Fourth Quarter And Full Year 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Boston Scientific (BSX) PT Raised to $45 at Credit Suisse
February 7, 2019 8:06 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Outperform rating following the company's 4Q earnings report. Organic sales growth guidance for 2019 is 7-8.5%. EPS guidance for 2019 is $1.53-1.58, which includes dilution recent... More
Boston Scientific (BSX) PT Raised to $45 at Raymond James
February 7, 2019 7:25 AM ESTRaymond James analyst Jayson Bedford raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Strong Buy rating.
"... we ultimately believe this guidance will prove conservative (similar to prior years) and believe the dizzying (in a good way) amount of new products should drive 8%+ organic growth."
... MoreBoston Scientific (BSX) PT Raised to $44 at Jefferies
February 6, 2019 1:37 PM ESTJefferies analyst Raj Denhoy raised the price target on Boston Scientific (NYSE: BSX) to $44.00 (from $43.00) while maintaining a Buy rating.
... MoreBoston Scientific (BSX) PT Raised to $42 at Piper Jaffray
February 6, 2019 1:00 PM ESTPiper Jaffray analyst Matt O'Brien raised the price target on Boston Scientific (NYSE: BSX) to $42.00 (from $40.00) while maintaining a Overweight rating.
O'Brien said the strong revenue guidance trumps slightly below Street EPS outlook.
... MoreBoston Scientific (BSX) Tops Q4 EPS by 2c, FY EPS Guidance Trails Views at Mid-Point
February 6, 2019 6:32 AM ESTBoston Scientific (NYSE: BSX) reported Q4 EPS of $0.39, $0.02 better than the analyst estimate of $0.37. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.56 billion.
GUIDANCE:
Boston Scientific sees Q1 2019 EPS of $0.35-$0.36, versus the consensus of $0.37.
The company estimates revenue growth for the first quarter of 2019, versus the prior year... More